MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$9,175K
EPS
-$0.14
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
2,135
2,231
5,482*
2,611
General and administrative
1,847
1,846
1,369*
1,587
Total operating expenses
3,982
4,077
6,850
4,198
Total operating loss
-3,982
-4,077
-6,850*
-4,198
Interest income
28
36
29*
39
Interest expense
2,004
1,988
1,860*
1,820
Change in fair value of derivative
-3,155
983
1,404*
-2,205
Total other income (expense)
-5,131
-969
-428*
-3,986
Net loss
-9,113
-5,046
-7,278*
-8,184
Preferred stock dividends
62
21
-15*
39
Net loss applicable to common stockholders
-9,175
-5,067
-7,263
-8,223
Basic EPS
-0.14
-0.08
-0.113
-0.13
Diluted EPS
-0.14
-0.08
-0.113
-0.13
Basic Average Shares
65,875,000
65,782,000
64,057,000
64,205,000
Diluted Average Shares
65,875,000
65,782,000
64,057,000
64,205,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss applicable
to common...
-$9,175K
(-20.98%↓ Y/Y)
Net loss
-$9,113K
(-21.17%↓ Y/Y)
Preferred stock dividends
$62K
(-1.59%↓ Y/Y)
Total other income
(expense)
-$5,131K
(-77.18%↓ Y/Y)
Total operating loss
-$3,982K
(13.90%↑ Y/Y)
Interest income
$28K
(7.69%↑ Y/Y)
Change in fair value of
derivative
-$3,155K
(-187.86%↓ Y/Y)
Interest expense
$2,004K
(9.75%↑ Y/Y)
Total operating
expenses
$3,982K
(-13.90%↓ Y/Y)
Research and development
$2,135K
(-34.53%↓ Y/Y)
General and
administrative
$1,847K
(35.41%↑ Y/Y)
Buy us a coffee
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)